摘要
Abstract
Objective:To compare the clinical efficacy of axitinib and sorafenib as first-line treatment for advanced renal cell carcinoma,and to explore whether axitinib could be used as a preferred first-line drug for advanced renal cell carcinoma.Methods:Sixty patients with advanced renal cell carcinoma from Haikou Municipal Hospital were enrolled in this study and divided into experimental group (n=30) and control group (n=30) according to a random number table.The experimental group received axitinib treatment and the control group received sorafenib treatment.Disease control rate (DCR),objective response rate (ORR),progression free survial (PFS),overall survival (OS),and adverse effects were evaluated and compared between two groups.Results:All patients in the two groups completed the experiment.There was no difference between the experimental group and the control group in DCR (83.33％ vs 80.00％,P＞0.05) and ORR (20.00％ vs 20.00％,P＞0.05).Significant difference in median PFS was found between the two groups (12.8 months of experimental group vs 10.1 months of control group,P＜0.05);however,there was no significant difference in the median OS between two groups (22.2 months vs 22.8 months,P＞0.05).The incidence of adverse reactions in the two groups was similar,mainly including hypertension,systemic reactions,hand foot skin syndrome,digestive system reaction and liver function damage (P＞0.05).No serious adverse effects were observed in both groups.Conclusion:Compared with sorafenib,axitinib significantly prolonged the median PFS in patients with advanced renal cell carcinoma,although the diseasecontrol rate,objective efficiency,overall survival,and adverse effects of two treatment regimen were comparable.Axitinib,the molecular targeted agent,can be used as a preferred first-line therapy for advanced renal cell carcinoma.关键词
晚期肾癌/阿昔替尼/索拉非尼/一线治疗/疗效Key words
advanced renal cell carcinoma/axitinib/sorafenib/first-line treatment/efficacy分类
医药卫生
